Ascendiant Capital Maintains Buy on Biolase, Lowers Price Target to $4
BenzingaApr 1 17:40
Biolase Analyst Ratings
BenzingaApr 1 17:38
Biolase's Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating
TipRanksMar 23 19:35
Biolase Analyst Ratings
BenzingaMar 23 01:37
Maxim Group Reaffirms Their Buy Rating on Biolase (BIOL)
TipRanksFeb 23 05:05
Positive Clinical Trial Results and Successful Cost Optimization Initiatives Bolster Buy Rating for Biolase Despite Lowered Price Target
TipRanksNov 15, 2023 02:15
Positive McGuire Study Results Boost Biolase's Market Potential and Justify Buy Rating
TipRanksNov 10, 2023 02:46
Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)
TipRanksJun 7, 2023 19:45
Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating
MT NewswiresMay 31, 2023 21:51
Lake Street Maintains Buy on Biolase, Lowers Price Target to $0.4
BenzingaMay 31, 2023 21:28
Lake Street Remains a Buy on Biolase (BIOL)
TipRanksMar 29, 2023 21:36
Benchmark Reiterates Speculative Buy on Biolase, Maintains $2 Price Target
BenzingaMar 29, 2023 20:00
Biolase Analyst Ratings
Benzinga Analyst RatingsJan 20, 2023 22:01
Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)
TipRanksJan 20, 2023 03:50
No Data
No Data